This late-stage clinical trial company focuses on preventing inflammation and acute organ injury. It is developing a platform of new drugs to prevent inflammation in the kidneys, liver and lungs...

To read the full story on AllPennyStocks.com, click here.

Arch Biopartners (TSXV:ARCH)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025 Plus de graphiques de la Bourse Arch Biopartners
Arch Biopartners (TSXV:ARCH)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025 Plus de graphiques de la Bourse Arch Biopartners